Data show lumateperone could offer lifeline for depression sufferers
Diurnal withdraws EMA orphan designation request for Efmody/Chronocort
EMA awards coveted PRIME designation for Janssen's CAR-T therapy
Lumateperone: Informazioni sul nuovo antipsicotico - Valerio Rosso
EMA again rejects Kyowa Kirin's MA for istradefylline for 'OFF' episod
lumateperone
Intra-Cellular Therapies, Inc.
![PDF] Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f590310d3891858f60d64afa3cbece654b006d47/21-Table1-1.png "PDF] Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone | Semantic Scholar")
PDF] Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone | Semantic Scholar
Synthetic Approaches to the New Drugs Approved during 2019 | Journal of Medicinal Chemistry
Lurasidone - Wikipedia
Lumateperone effektiv und sicher bei Schizophrenie | Gelbe Liste
Lumateperone | New Drug Approvals
PDF) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. (2019) | Filippo Corponi | 33 Citations
PDF) Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Lumateperone: Informazioni sul nuovo antipsicotico - Valerio Rosso
PDF) Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Lumateperone | New Drug Approvals
Alnylam promises swift access after Oxlumo EMA approval
Lumateperone | New Drug Approvals
PDF) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. (2019) | Filippo Corponi | 33 Citations
EMA experts meet with African regulators to discuss opportunities for
EMA starts rolling review of COVID-19 vaccine Vidprevtyn
Frontiers | Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy
